Clinical Trial Update: Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating daratumumab monotherapy and its effects on bone parameters in patients with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN